Dmed Diagnostic was created with the aim of bringing to both the medical community from clinical laboratories and clinical users, the new diagnostic technologies for the early diagnosis and treatment of high-risk myocardial infarction patients (MI,) developed by the Japanese multinational LSI Medience, represented in Chile by Dmed INC. In Dmed, our executives and employees are committed not only to the well-being of the patients but also to ensure they receive prompt, responsible, and quality treatment. Therefore, all of our efforts are focused toward providing professionals and health institutions with only the best clinical and technological solutions operating worldwide.


Dmed I Diagnostic markets the innovative Pathfast system, developed by LSI Medience, for the early diagnosis of high-risk myocardial patients. It only takes 15 minutes, with whole blood units.

  • Sensitive Troponin I
  • Myoglobin
  • CK-MB mass
  • D-dimer
  • NT-pro BNP
  • hsCRP
  • HCG
  • PATHFAST® Presepsin is a chemiluminescent enzyme immunoassay for the quantitative measurement of presepsin concentration in whole blood or plasma. PATHFAST® Presepsin can be used as an aid in the diagnosis and prognosis of sepsis, in the assessment of the degree of septic severity, and in the risk stratification of critically ill septic patients.


Dmed Diagnostic markets and distributes its Pathfast system to all the regions of the country.  The experience learned over 8 years of existence within the health sector has enabled us to have a wide presence in the Institutional market (Hospitals, Clinics, physician's offices and others), resulting in close, and personal contact with our customers.